Skip to content
MenuOpen navigation menu

Real moms, real GLP-1 talk

Hair Shedding on GLP-1s: What the Evidence Supports

What Wegovy and Zepbound labels report about hair loss, why timing alone does not establish the cause, and what to discuss before buying a remedy.

Written by — editorial research, not medical advice
On this page

Hair shedding deserves a clearer explanation

Hair shedding can be distressing whether someone else notices it or not. I would want to know what the label reports, which other causes need consideration, and whether the pattern is diffuse or patchy. A medication’s timing can be relevant without proving that it is the only cause.

I would not promise that hair loss is always temporary or that it will recover on a particular schedule. An individual assessment matters more than a reassuring story. The point of reading the evidence is to prepare a useful conversation, not to tell someone what happened to a different person’s hair.

It is on the label, with a number

The prescribing information provides actual trial rates rather than a recovery story.

The Wegovy label lists it, and — unusually — it breaks the numbers down by sex, which almost nobody quotes.

In the adult trials on the 2.4 mg dose, hair loss was reported by 3.3% of patients overall. Split by sex, that is 4% of women against 0.9% of men. On placebo it was 1% overall: 2% of women, and none of the men1. At the higher 7.2 mg dose the gap widens again — 5.8% overall, but 8.4% of women against 0.2% of men1. The Zepbound label lists it too, running around 4–5% against 1%2.

Hair loss is one of the women's side effects almost never mentioned in a welcome email. Women run roughly four times the male rate at the standard dose and forty times it at the high one: small percentages, real effect, heavily concentrated in us.

(If you have seen "4% versus 0%" quoted for Wegovy, that pairing is from the pediatric trial in 12-to-17-year-olds. The adult comparator is not zero.)

One more line from the label worth holding onto: hair loss reactions in treated patients "were associated with weight reduction"1 — the label itself frames this as a consequence of losing weight rather than a direct effect of the drug on hair.

There is proper research now as well. A 2025 retrospective cohort study in the Journal of the American Academy of Dermatology looked specifically at GLP-1 medications and hair loss3, a 2025 systematic review pulled together what is known — noting the signal was first flagged in the FDA's adverse-event reporting system4 — and a scoping review cataloged the dermatologic findings reported with semaglutide5.

So: documented, studied, and still not something anyone tells you at the start.

Why the timeline can be confusing

The timing is the part that made it make sense.

What dermatologists describe here is the pattern where a physiological stress — rapid weight loss, a big drop in intake, illness, childbirth — pushes a lot of hairs into their resting phase at once. They do not fall out then. They fall out when the next growth cycle pushes them out, which is why the shedding shows up two to four months after the thing that caused it, and why it feels like it comes out of nowhere.

A delay between a trigger and visible shedding can make the connection difficult to recognize. I would bring a timeline of weight change, illness, childbirth, diet and medication changes rather than assume only the most recent dose matters.

That possible pattern does not establish the cause or prognosis in every person. I would ask whether the findings fit telogen effluvium or whether the scalp and hair pattern suggest something else. Waiting for an assumed recovery is not the right response to every kind of loss.

What I would ask before trying a remedy

Reviewing nutrition. I would describe what I can comfortably eat, including how much protein I manage, and whether intake has fallen sharply. A clinician or dietitian can assess adequacy without treating a particular protein target as a proven hair-regrowth treatment.

Discussing the treatment response. I would ask whether the pace of weight change and current dose are appropriate. The cited studies do not prove that holding a dose reverses shedding, so I would not change my own prescription to test that idea.

Asking about other causes. Depending on the symptoms and history, the clinician may consider iron status, thyroid health or other contributors. I would ask which tests are justified rather than assume that everyone needs the same panel.

Checking the promise before buying. I would ask what diagnosis a supplement or treatment addresses, what benefit is supported and whether it could interfere with another medicine. An online before-and-after photo does not establish that a product caused regrowth.

When it is not this

Worth saying plainly, because "it is just the GLP-1" can hide something else. Patchy loss rather than a general thinning, loss at the front hairline specifically, scalp pain or scaling, or shedding that is still getting worse past six months — those are reasons to see someone rather than wait it out. Thyroid problems and iron deficiency both cause hair loss and both are ordinary, testable things.

Preparing for the next appointment

A concern about appearance does not become trivial because treatment is helping another part of health. I would mention how much the shedding is affecting daily life as well as describing the physical pattern. That gives the clinician a clearer picture of the problem to address.

Before the next visit, I would collect the timeline, a few comparable photographs if useful, and a list of current medicines and supplements. Switching to a different molecule should not be assumed to solve hair loss without an assessment, since both labels report it. I would ask what to watch for and when to return if shedding continues.

Frequently asked questions

Is hair loss a real GLP-1 side effect?

Yes, and the Wegovy label breaks it down by sex. On the adult 2.4 mg dose, hair loss was reported by 3.3% of patients overall — 4% of women against 0.9% of men — versus 1% on placebo, which was 2% of women and none of the men. At the 7.2 mg dose it was 5.8% overall, 8.4% of women against 0.2% of men. The Zepbound label lists it at roughly 4-5% against 1%. Note the widely quoted 4% versus 0% pairing is from the pediatric trial, not the adult one. There is also a 2025 retrospective cohort study in the Journal of the American Academy of Dermatology and a 2025 systematic review.

When does the shedding start?

The cause matters. Some stress-related diffuse shedding appears after a delay, but timing alone does not identify telogen effluvium or guarantee that hair loss will resolve. Bring a timeline and ask about the pattern.

How do you stop hair loss from a GLP-1?

Ask for an assessment of the pattern, symptom timing, nutrition and other potential causes. Tests and treatment should fit the individual history. Do not change a prescription or assume a supplement will restore growth without advice.

When should I see someone about it?

Ask for assessment of patchy loss, scalp pain or scaling, a changing hairline, or persistent or worsening shedding. You do not need to wait six months to raise a concern. Thyroid problems, nutrition and other causes may need review; testing should fit the history and examination.

References

  1. U.S. Food and Drug Administration (2025). Wegovy (semaglutide) injection — Prescribing Information (adults, 2.4 mg: hair loss 3.3% overall — 4% female vs 0.9% male — against 1% placebo, 2% female; 7.2 mg: 5.8% overall, 8.4% female; associated with weight reduction; the 4% vs 0% pairing is the paediatric trial). DailyMed / FDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. U.S. Food and Drug Administration (2025). Zepbound (tirzepatide) injection — Prescribing Information (hair loss 4-5% vs 1% placebo). DailyMed / FDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  3. Burke O, Sa B, Cespedes DA, Sechi A, Tosti A. (2025). Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study. Journal of the American Academy of Dermatology. https://pubmed.ncbi.nlm.nih.gov/39863171/
  4. Alsuwailem OA, Alanazi R, Almutairi HM, et al. (2025). Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review. Cureus. https://pubmed.ncbi.nlm.nih.gov/41111833/
  5. Tran MM, Mirza FN, Lee AC, et al. (2024). Dermatologic findings associated with semaglutide use: A scoping review. Journal of the American Academy of Dermatology. https://pubmed.ncbi.nlm.nih.gov/38554940/

One mom to another, not a doctor: everything here is for learning and figuring out your options, not medical advice, a diagnosis, or a plan for your body. Pregnancy planning and breastfeeding need advice for the exact medicine and formulation. Before you start, stop, or change anything, talk it through with a clinician who actually knows your history.